The Risk/Benefit Analysis of Oral Anticoagulant Treatment in Atrial Fibrillation Using HAS-BLED and CHA2DS2-VASc Score

Publié en ligne: 19 janv. 2016

Pages: 269 - 272

Reçu: 09 déc. 2014

Accepté: 04 juin 2015

DOI: https://doi.org/10.1515/amma-2015-0056

Mots clés

atrial fibrillation, thromboembolic events, bleeding events, oral anticoagulant treatment

© 2015 Silivastru (Cozlea) Ionela et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.